| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 2500% | ₹728.75 0% | 2,800 | ₹0.35 0% | 00% |
| 00% | ₹668.1 0% | 2,950 | - | - |
| - | - | 3,050 | ₹0.75 0% | 6,7500% |
| 2500% | ₹509 0% | 3,100 | ₹2.1 0% | 5,7500% |
| 2500% | ₹408 0% | 3,200 | ₹3.2 39.13% | 14,750-3.27% |
| 00% | ₹398.15 0% | 3,250 | ₹3 0% | 8,0000% |
| 00% | ₹291 0% | 3,300 | ₹3.95 -8.13% | 43,50010.12% |
| 5000% | ₹280.55 0% | 3,350 | ₹5.1 0% | 8,7506.06% |
| 10,2507.89% | ₹247.3 2.44% | 3,400 | ₹9.7 31.97% | 44,5004.09% |
| 5000% | ₹182.25 0% | 3,450 | ₹13.75 6.58% | 10,500-2.32% |
| 24,500-1.01% | ₹154.4 0.58% | 3,500 | ₹17.45 -11.64% | 58,250-3.31% |
| 12,500-1.96% | ₹124.65 -0.43% | 3,550 | ₹30 -4.3% | 29,5004.42% |
| 54,500-2.24% | ₹75 -7.97% | 3,600 | ₹47.1 -3.68% | 35,25011.02% |
| 53,75033.54% | ₹53.65 -3.5% | 3,650 | ₹67.75 -8.38% | 9,0009.09% |
| 60,750-7.60% | ₹34.85 -4.91% | 3,700 | ₹102.25 0.04% | 31,000-5.34% |
| 24,750-1% | ₹24.3 2.1% | 3,750 | ₹144.15 0% | 9,5000% |
| 84,250-3.98% | ₹14 -7.28% | 3,800 | ₹211.8 0% | 6,5000% |
| 23,7507.95% | ₹9.45 -6.89% | 3,850 | ₹249.5 0% | 2500% |
| 67,5003.84% | ₹6.75 -0.73% | 3,900 | ₹294.6 0% | 1,0000% |
| 6,2500% | ₹6.05 0% | 3,950 | - | - |
| 74,500-0.99% | ₹4.1 -7.86% | 4,000 | - | - |
| 5,0000% | ₹2.55 8.51% | 4,050 | - | - |
| 65,000-0.76% | ₹2.3 -13.2% | 4,100 | - | - |
| 2,0000% | ₹3 0% | 4,200 | - | - |
The transaction involves around 38.75 lakh shares, priced at ₹1,600 each, being offloaded by JB Chemicals employees who recently converted their stock options.
The acquisition values JB Chemicals at ₹25,689 crore on a fully diluted basis, according to the company’s official announcement.
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
